Malcolm Robert Hill, III
Pharmacy at Lusk Blvd, San Diego, CA
License number
Colorado 12647
Issued Date
Nov 25, 1988
Renew Date
Oct 31, 1997
Expiration Date
Oct 31, 1997
Type
Pharmacist
Address
Address
7475 Lusk Blvd, San Diego, CA 92121
Professional information
Cso At Meritage Pharma, Inc.
Position:
CSO at Meritage Pharma, Inc.
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
Meritage Pharma, Inc.
-
CSO
Dura Pharmaceuticals
1992 - 2001
-
Vice President Clinical Development
Methods Of Dry Powder Inhalation
US Patent:
6116237, Sep 12, 2000
Filed:
Apr 24, 1997
Appl. No.:
8/847287
Inventors:
Robert Schultz - San Diego CA
Clyde Witham - San Diego CA
Malcolm Hill - San Diego CA
Clyde Witham - San Diego CA
Malcolm Hill - San Diego CA
Assignee:
Dura Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61M 1500
US Classification:
12820315
Abstract:
A method for inhalation of a dry powder drug includes the steps of providing a dry powder drug composition having a drug particle size of from about 1-7 microns and a mass median aerodynamic diameter of the delivered aerosol of from about 3. 5 to 5. 5 microns. This composition is loaded into an inhaler which is generally flow rate independent, and with the inhaler having an inspiration flow resistance of about 0. 12 to 0. 21 (cmH. sub. 2 O). sup. 1/2 over the range of about 15-60 L/min. The patient inhales the drug composition from the inhaler with an inspiration flow rate of about 15-60 L/min, resulting in a delivery efficiency measured by respirable fraction greater than 20%.
Methods Of Treatment For Esophageal Inflammation
US Patent:
2012016, Jun 28, 2012
Filed:
Jun 24, 2011
Appl. No.:
13/168601
Inventors:
Malcolm Hill - San Diego CA, US
Elaine Phillips - San Diego CA, US
Elaine Phillips - San Diego CA, US
Assignee:
MERITAGE PHARMA, INC. - San Diego CA
International Classification:
A61K 9/12, A61P 1/00, A61P 29/00, A61K 31/56
US Classification:
424 43, 514179
Abstract:
Provided herein are methods for treating gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus and/or reducing local and systemic exposure and/or side effects resulting therefrom. Provided herein are methods for diagnosing gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus. Also provided herein are methods for inducing remission of eosinophilic infiltration of the esophagus